Drugs / SARS-CoV-2 convalescent plasma
SARS-CoV-2 convalescent plasma
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05595538 | Jun → Sep 2020 | COVID-19 | Hospital Regional Dr. Rafael Estévez | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04384497 | May → Jun 2020 | COVID-19 | Joakim Dillner | Completed | No outcome recorded |
| Phase 1/2 | NCT04390178 | Apr → Jun 2020 | COVID-19 | Joakim Dillner | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04373460 | Jun 2020 → Jan 2022 | COVID-19 | Johns Hopkins University | Completed | Mixed |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04649879 | Dec 2020 → Jan 2022 | COVID-19 | Joakim Dillner | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04836260 | Apr → Dec 2021 | COVID-19, immunodeficiency disease | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04374370 | — | COVID-19 | AdventHealth | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 convalescent plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04836260 ↗ |
| Modality | Protein / enzyme biologic | “Polyclonal convalescent plasma” PMID 35353960 ↗ Mar 2022 |
| Route | Other | “received a transfusion” PMID 35353960 ↗ Mar 2022 |